ALERTS & COVID-19 UPDATES Learn more: COVID-19 Resources; COVID-19 Testing; Vaccine Info; Visitor Policy; Support Us

[LCID Study Number: 2018-033]

A 3-Arm, Multicenter, Double-Blind, Placebo-Controlled, Randomized Study to Assess The Efficacy And Safety Of Ads-5102 Amantadine Extended Release Capsules In Multiple Sclerosis Patient With Walking Impairment

The primary objective of this study is to evaluate the efficacy of 274 mg ADS-5102 in subjects with MS and walking impairment as measured by the T25FW, Timed Up and Go (TUG) test, and the 2-minute Walk Test (2MWT) AT WEEK 16.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-372-7194